Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?
Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.
Gespeichert in:
| Autor*in: |
Niegisch, Günter [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013 |
|---|
| Umfang: |
3 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise - Feng, Jing ELSEVIER, 2018, official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:64 ; year:2013 ; number:3 ; pages:355-357 ; extent:3 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.eururo.2013.06.002 |
|---|
| Katalog-ID: |
ELV01682606X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV01682606X | ||
| 003 | DE-627 | ||
| 005 | 20230623132013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eururo.2013.06.002 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013009000028.pica |
| 035 | |a (DE-627)ELV01682606X | ||
| 035 | |a (ELSEVIER)S0302-2838(13)00600-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 500 |q VZ |
| 084 | |a 33.25 |2 bkl | ||
| 084 | |a 31.00 |2 bkl | ||
| 100 | 1 | |a Niegisch, Günter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? |
| 264 | 1 | |c 2013 | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease. | ||
| 700 | 1 | |a Lorch, Anja |4 oth | |
| 700 | 1 | |a Droller, Michael J. |4 oth | |
| 700 | 1 | |a Lavery, Hugh J. |4 oth | |
| 700 | 1 | |a Stensland, Kristian D. |4 oth | |
| 700 | 1 | |a Albers, Peter |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Feng, Jing ELSEVIER |t Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |d 2018 |d official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology |g Amsterdam [u.a.] |w (DE-627)ELV000464341 |
| 773 | 1 | 8 | |g volume:64 |g year:2013 |g number:3 |g pages:355-357 |g extent:3 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.eururo.2013.06.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 33.25 |j Thermodynamik |j statistische Physik |q VZ |
| 936 | b | k | |a 31.00 |j Mathematik: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 64 |j 2013 |e 3 |h 355-357 |g 3 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
g n gn |
|---|---|
| matchkey_str |
niegischgnterlorchanjadrollermichaeljlav:2013----:eajvnceohrpiptetwtmslivsvbadrac |
| hierarchy_sort_str |
2013 |
| bklnumber |
33.25 31.00 |
| publishDate |
2013 |
| allfields |
10.1016/j.eururo.2013.06.002 doi GBVA2013009000028.pica (DE-627)ELV01682606X (ELSEVIER)S0302-2838(13)00600-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Niegisch, Günter verfasserin aut Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? 2013 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease. Lorch, Anja oth Droller, Michael J. oth Lavery, Hugh J. oth Stensland, Kristian D. oth Albers, Peter oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:64 year:2013 number:3 pages:355-357 extent:3 https://doi.org/10.1016/j.eururo.2013.06.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 64 2013 3 355-357 3 045F 610 |
| spelling |
10.1016/j.eururo.2013.06.002 doi GBVA2013009000028.pica (DE-627)ELV01682606X (ELSEVIER)S0302-2838(13)00600-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Niegisch, Günter verfasserin aut Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? 2013 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease. Lorch, Anja oth Droller, Michael J. oth Lavery, Hugh J. oth Stensland, Kristian D. oth Albers, Peter oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:64 year:2013 number:3 pages:355-357 extent:3 https://doi.org/10.1016/j.eururo.2013.06.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 64 2013 3 355-357 3 045F 610 |
| allfields_unstemmed |
10.1016/j.eururo.2013.06.002 doi GBVA2013009000028.pica (DE-627)ELV01682606X (ELSEVIER)S0302-2838(13)00600-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Niegisch, Günter verfasserin aut Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? 2013 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease. Lorch, Anja oth Droller, Michael J. oth Lavery, Hugh J. oth Stensland, Kristian D. oth Albers, Peter oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:64 year:2013 number:3 pages:355-357 extent:3 https://doi.org/10.1016/j.eururo.2013.06.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 64 2013 3 355-357 3 045F 610 |
| allfieldsGer |
10.1016/j.eururo.2013.06.002 doi GBVA2013009000028.pica (DE-627)ELV01682606X (ELSEVIER)S0302-2838(13)00600-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Niegisch, Günter verfasserin aut Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? 2013 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease. Lorch, Anja oth Droller, Michael J. oth Lavery, Hugh J. oth Stensland, Kristian D. oth Albers, Peter oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:64 year:2013 number:3 pages:355-357 extent:3 https://doi.org/10.1016/j.eururo.2013.06.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 64 2013 3 355-357 3 045F 610 |
| allfieldsSound |
10.1016/j.eururo.2013.06.002 doi GBVA2013009000028.pica (DE-627)ELV01682606X (ELSEVIER)S0302-2838(13)00600-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Niegisch, Günter verfasserin aut Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? 2013 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease. Lorch, Anja oth Droller, Michael J. oth Lavery, Hugh J. oth Stensland, Kristian D. oth Albers, Peter oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:64 year:2013 number:3 pages:355-357 extent:3 https://doi.org/10.1016/j.eururo.2013.06.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 64 2013 3 355-357 3 045F 610 |
| language |
English |
| source |
Enthalten in Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise Amsterdam [u.a.] volume:64 year:2013 number:3 pages:355-357 extent:3 |
| sourceStr |
Enthalten in Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise Amsterdam [u.a.] volume:64 year:2013 number:3 pages:355-357 extent:3 |
| format_phy_str_mv |
Article |
| bklname |
Thermodynamik statistische Physik Mathematik: Allgemeines |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| authorswithroles_txt_mv |
Niegisch, Günter @@aut@@ Lorch, Anja @@oth@@ Droller, Michael J. @@oth@@ Lavery, Hugh J. @@oth@@ Stensland, Kristian D. @@oth@@ Albers, Peter @@oth@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000464341 |
| dewey-sort |
3610 |
| id |
ELV01682606X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV01682606X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623132013.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eururo.2013.06.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013009000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV01682606X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0302-2838(13)00600-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.25</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Niegisch, Günter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lorch, Anja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Droller, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lavery, Hugh J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stensland, Kristian D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albers, Peter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Feng, Jing ELSEVIER</subfield><subfield code="t">Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise</subfield><subfield code="d">2018</subfield><subfield code="d">official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000464341</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:64</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:355-357</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.eururo.2013.06.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.25</subfield><subfield code="j">Thermodynamik</subfield><subfield code="j">statistische Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.00</subfield><subfield code="j">Mathematik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">64</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="h">355-357</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Niegisch, Günter |
| spellingShingle |
Niegisch, Günter ddc 610 ddc 500 bkl 33.25 bkl 31.00 Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? |
| authorStr |
Niegisch, Günter |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000464341 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 500 - Natural sciences & mathematics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? |
| topic |
ddc 610 ddc 500 bkl 33.25 bkl 31.00 |
| topic_unstemmed |
ddc 610 ddc 500 bkl 33.25 bkl 31.00 |
| topic_browse |
ddc 610 ddc 500 bkl 33.25 bkl 31.00 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a l al m j d mj mjd h j l hj hjl k d s kd kds p a pa |
| hierarchy_parent_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| hierarchy_parent_id |
ELV000464341 |
| dewey-tens |
610 - Medicine & health 500 - Science |
| hierarchy_top_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000464341 |
| title |
Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? |
| ctrlnum |
(DE-627)ELV01682606X (ELSEVIER)S0302-2838(13)00600-3 |
| title_full |
Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? |
| author_sort |
Niegisch, Günter |
| journal |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| journalStr |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
355 |
| author_browse |
Niegisch, Günter |
| container_volume |
64 |
| physical |
3 |
| class |
610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Niegisch, Günter |
| doi_str_mv |
10.1016/j.eururo.2013.06.002 |
| dewey-full |
610 500 |
| title_sort |
neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? |
| title_auth |
Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? |
| abstract |
Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease. |
| abstractGer |
Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease. |
| abstract_unstemmed |
Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| container_issue |
3 |
| title_short |
Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? |
| url |
https://doi.org/10.1016/j.eururo.2013.06.002 |
| remote_bool |
true |
| author2 |
Lorch, Anja Droller, Michael J. Lavery, Hugh J. Stensland, Kristian D. Albers, Peter |
| author2Str |
Lorch, Anja Droller, Michael J. Lavery, Hugh J. Stensland, Kristian D. Albers, Peter |
| ppnlink |
ELV000464341 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.eururo.2013.06.002 |
| up_date |
2024-07-06T20:28:50.065Z |
| _version_ |
1803862912602734592 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV01682606X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623132013.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eururo.2013.06.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013009000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV01682606X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0302-2838(13)00600-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.25</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Niegisch, Günter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lorch, Anja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Droller, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lavery, Hugh J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stensland, Kristian D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albers, Peter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Feng, Jing ELSEVIER</subfield><subfield code="t">Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise</subfield><subfield code="d">2018</subfield><subfield code="d">official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000464341</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:64</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:355-357</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.eururo.2013.06.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.25</subfield><subfield code="j">Thermodynamik</subfield><subfield code="j">statistische Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.00</subfield><subfield code="j">Mathematik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">64</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="h">355-357</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401514 |